Merck News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

14.06.16	RVNC Wrinkled, MRNS Jolted As Study Fails, BSTC Abuzz, FDA Snubs KMPH (RTTNews)
13.06.16	Merck's Insulin Glargine, MK-1293, Met Primary Endpoint In Two Phase 3 Studies (RTTNews)
10.06.16	MRK Opens Wallet, VRX To Face FDA Panel In July, SPHS Vaults On Trial Data (RTTNews)
10.06.16	Merck To Buy Afferent Pharmaceuticals (RTTNews)
09.06.16	Merck: Healthcare Business At Forefront Of Growth Strategy For Africa (RTTNews)
05.06.16	Merck Updates Findings From Study Evaluating KEYTRUDA (RTTNews)
04.06.16	Merck: KEYTRUDA New Data To Be Presented At ASCO (RTTNews)
30.05.16	AZN's Falcon Hits Goal, FDA Approves MS Drug, CANF Awaits Data In June (RTTNews)
29.05.16	Biotech Stocks Facing FDA Decision In June (RTTNews)
27.05.16	Merck Gets Positive CHMP Opinion For ZEPATIER In EU (RTTNews)
24.05.16	MSD Animal Health Receives Marketing Approval For BRAVECTO In EU - Quick Facts (RTTNews)
05.05.16	Merck Q1 Adj. Profit Tops View, But Sales Miss; Lifts FY16 Adj. EPS Outlook (RTTNews)
05.05.16	Merck & Co Inc. Q1 Earnings Rise 2% (RTTNews)
26.04.16	Blockbusters Falling Off Patent Cliff In 2016 (RTTNews)
25.04.16	Merck: Chinese Phase III Study With Erbitux Plus FOLFOX Meets Primary Endpoint (RTTNews)
18.04.16	Merck Gets FDA Breakthrough Therapy Designation For KEYTRUDA In CHL (RTTNews)
16.04.16	NY Attorney General Sues CDPHP For Unlawfully Denying Coverage Of HCV Treatment (RTTNews)
07.04.16	Merck To Present Updates On Anti-infective Therapies At ECCMID (RTTNews)
06.04.16	The U.S. Gets 2nd Biosimilar, ORMP Awaits Data This Qtr, PFE Hits Mark In OPAL (RTTNews)
25.03.16	Gilead To Pay $200 Mln To Merck, Ionis Pharma In Hepatitis C Drug Patent Suit (RTTNews)
23.03.16	LLY Gets FDA Nod, MRK Scores Legal Win, AFFX Pursued By Origin Technologies (RTTNews)
23.03.16	Ionis And Merck Receive Positive Verdict On Gilead HCV Drug Patent Case (RTTNews)
22.03.16	MSD Animal Health Gets EMA Positive Opinion For BRAVECTO Spot-On For Cats & Dogs (RTTNews)
08.03.16	Sanofi Pasteur, Merck To End Joint Vaccines Operations In Europe - Quick Facts (RTTNews)
08.03.16	Merck 2015 Net Income Decreases; Proposes To Increase Dividend - Quick Facts (RTTNews)
07.03.16	Merck Says FDA Accepts Supplemental Biologics License Application For Keytruda (RTTNews)
03.03.16	Merck, Pfizer, Verastem Combination Trial Of Avelumab &VS-6063 In Ovarian Cancer (RTTNews)
22.02.16	Merck Meets Primary Endpoints In Phase 3 Study Of Isentress In HIV-1 Adults (RTTNews)
22.02.16	Myriad Expands Diagnostic Research Collaboration With Tesaro, Merck (RTTNews)
16.02.16	CLVS Gets Panel Date, XBIO Abuzz, FDA Says No To Broader Use Of Zetia, Vytorin (RTTNews)
16.02.16	FDA Turns Down Merck's Request For Broader Use Of Zetia, Vytorin (RTTNews)
05.02.16	SCLN Settles FCPA Charges, OGXI On Cost Discipline Mode, Shire To Face FDA (RTTNews)
04.02.16	Merck Announces FDA Approval Of Expanded Indication For EMEND - Quick Facts (RTTNews)
03.02.16	Merck Q4 Adj. Profit Beats View, But Sales Miss (RTTNews)
03.02.16	Merck & Co Inc. Announces 4% Rise In Q4 Profit (RTTNews)
29.01.16	Data Due Mid Year For CORT, New Addition To HCV Armory, EXEL Gets FDA Date (RTTNews)
28.01.16	NEOS Gets Much Needed Attention, AKRX Breathes Easy, INCY Halts Study (RTTNews)
27.01.16	Merck: FDA Accepts For Review BLA For Bezlotoxumab - Quick Facts (RTTNews)
25.01.16	Affimed To Collaborate With Merck To Evaluate AFM13 In Combination With KEYTRUDA (RTTNews)
15.01.16	Merck KGaA Announces Favorable English Court Ruling On Name Use (RTTNews)
15.01.16	Merck Agrees To Settle Class Action Lawsuit On Vioxx, Expects Charge In Q4 (RTTNews)
23.12.15	WHO To Review Merck's Investigation Ebola Vaccine For Emergency Use Assessment (RTTNews)
20.12.15	Merck's KEYTRUDA Significantly Improves Survival Vs Chemotherapy In NSCLC (RTTNews)
18.12.15	Merck Anticipates European Commission Decision On Elbasvir In Mid-2016 (RTTNews)
16.12.15	Reversal Of Misfortune : Merck's Bridion Finally Gets FDA Approval (RTTNews)
16.12.15	Merck : FDA Approves Expanded Age Indication For GARDASIL 9 In Males (RTTNews)
16.12.15	FDA Okays Merck's Surgery Drug Bridion (RTTNews)
15.12.15	FDA Panel Fails To Back Merck's Cholestrol Drug Vytorin For Heart Ailments (RTTNews)
10.12.15	Lilly And Merck Expand Immuno-Oncology Collaboration - Quick Facts (RTTNews)
07.12.15	Merck: Samsung Bioepis Receives Approval Of RENFLEXIS In Korea - Quick Facts (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

19.11.24		Schwacher Handel: Dow Jones beendet den Dienstagshandel mit Verlusten
19.11.24		Gute Stimmung in New York: NASDAQ 100 letztendlich im Plus
19.11.24		Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein
19.11.24		Gewinne in New York: NASDAQ 100 legt zu
19.11.24		Dow Jones-Handel aktuell: So entwickelt sich der Dow Jones aktuell
19.11.24		Angespannte Stimmung in Europa: STOXX 50 verliert schlussendlich
19.11.24		Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer

19.11.24

Schwacher Handel: Dow Jones beendet den Dienstagshandel mit Verlusten

19.11.24

Gute Stimmung in New York: NASDAQ 100 letztendlich im Plus

19.11.24

Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein

19.11.24

Gewinne in New York: NASDAQ 100 legt zu

19.11.24

Dow Jones-Handel aktuell: So entwickelt sich der Dow Jones aktuell

19.11.24

Angespannte Stimmung in Europa: STOXX 50 verliert schlussendlich

19.11.24

Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Merck Co.

Aktien Top/Flop

Merck Peer Group Nachrichten

Meistgelesene Nachrichten